In AIH, failure to maintain remission was associated with increased cT1, not FibroScan liver stiffness or ELF. Baseline cT1 also predicted subsequent biochemical relapse, whereas liver stiffness or ELF did not, supporting LiverMultiScan as a sensitive tool for risk stratification and earlier intervention.